methotrexate

Upfront CTx only regimens used were classified into three groups to reflect disease treatment conventions: standard-dose, high-dose (intensified regimens of sufficient dosage to require stem cell support) and those including intraventricular methotrexate (IVT-MTX)...With outcomes established, clinical trials are now encouraged to focus on quality-of-life following different intensified approaches to identify the kindest curative strategies. Cancer Research UK, Children with Cancer UK, Children's Cancer North, Star for Harris, JGW Patterson Foundation, Little Hero and Blue Skye Thinking.

Blinatumomab was administered after one cycle of high-dose methotrexate/cytarabine, resulting in MRD negativity after one cycle...Inotuzumab ozogamicin induced a second hematological remission with MRD negativity, although disease control was not durable. This case highlights the importance of repeat immunophenotypic and cytogenetic assessment at relapse after blinatumomab treatment.

Despite multiple immunosuppressive therapies, including glucocorticoids, methotrexate, cyclophosphamide and biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin (IL)-1 and IL-6, high disease activity persisted. To the best of our knowledge, this is the first report of successful treatment of RP-associated aortitis with bimekizumab, highlighting the potential role of IL-17A and IL17F in RP pathogenesis. These findings provide a foundation for further exploration of IL-17 inhibition in RP-associated vasculitis.

She underwent therapy with rituximab, methotrexate, procarbazine, and vincristine followed by high-dose cytarabine, achieving temporary remission; however, relapse occurred 1 month after consolidation therapy. This case also suggests a potential therapeutic role for tirabrutinib in early-relapsing LC. https://thejns.org/doi/10.3171/CASE26337.

SLC30A9 maintains a low-zinc environment and mitochondrial integrity, thereby inhibiting mtDNA-mediated cGAS-STING pathway activation. Targeting SLC30A9 to disrupt this protective mechanism provides a novel therapeutic strategy for overcoming chemoresistance in osteosarcoma.

The ICAM-1-derived cIBR peptide selectively binds to the I-domain of LFA-1, a receptor highly expressed on leukemia T cells; thus, the MTX-cIBR conjugate can be used to target methotrexate (MTX) to leukemic T cells and reduce its off-target toxicity...Computational analyses further demonstrated that MTX exhibited lower binding free energy (ΔG) and greater binding stability toward DHFR than MTX-cIBR. These findings suggest that MTX-cIBR retains selective cytotoxic activity toward LFA-1-expressing leukemia T cells through altered cellular uptake and exhibits different interaction characteristics with DHFR compared with unconjugated MTX.

P2, N=30, Completed, Australasian Leukaemia and Lymphoma Group | Active, not recruiting --> Completed

Additionally, they bolster the intracellular antioxidant defense system. These findings unveil a sophisticated regulatory network and suggest that with strict control of systemic exposure through optimized topical formulations, these FDA-approved agents could be further investigated as potential localized treatments for pigmentary disorders.

In conclusion, our data indicate that curcumin attenuates MTX-induced neurobehavioral deficits and biochemical alterations. The protective effects of curcumin are likely mediated, at least in part, by restoring redox homeostasis and modulating TNF-α/BDNF signaling, suggesting a potential therapeutic avenue for mitigating chemotherapy-induced neurotoxicity.

The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit-risk profile for long-term RA treatment.

All patients received nonsteroidal anti-inflammatory drugs as initial therapy, and one required additional treatment with oral methotrexate and adalimumab. Serum cytokine analysis was performed in three cases, revealing elevated levels of both pro- and anti-inflammatory cytokines, such as interleukin (IL)-6, IL-10, and IL-33 in the pre-treatment state. These cases underscore the clinical heterogeneity of CNO/CRMO.

Stereotactic brain biopsy confirmed PCNSL, and the patient was initiated on high-dose methotrexate-based chemotherapy with adjunctive dexamethasone. This case highlights that PCNSL can occur despite immunologic preservation in HIV and may present acutely with seizures. Early contrast-enhanced MRI, careful timing of corticosteroid use relative to biopsy, and timely referral are essential, particularly in resource-limited settings.